Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
Dyana T. Saenz(The University of Texas MD Anderson Cancer Center), Warren Fiskus(The University of Texas MD Anderson Cancer Center), Yimin Qian(Arvinas (United States)), Taghi Manshouri(The University of Texas MD Anderson Cancer Center), Kimal Rajapakshe(Baylor College of Medicine), Kanak Raina(Arvinas (United States)), Kevin Coleman(Arvinas (United States)), Andrew P. Crew(Arvinas (United States)), Angela Shen(Arvinas (United States)), Christopher P. Mill(The University of Texas MD Anderson Cancer Center), Baohua Sun(The University of Texas MD Anderson Cancer Center), P Qiu(Georgia Institute of Technology), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Courtney DiNardo(The University of Texas MD Anderson Cancer Center), MS Kim(The University of Texas MD Anderson Cancer Center), Agnieszka Nowak(The University of Texas MD Anderson Cancer Center), Cristian Coarfa(Baylor College of Medicine), Craig M. Crews(Yale University), Srđan Verstovšek(The University of Texas MD Anderson Cancer Center), Kapil N. Bhalla(The University of Texas MD Anderson Cancer Center)
Cited by 183Open Access